William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sami Corwin has given his Buy rating due to a combination of factors surrounding Krystal Biotech’s innovative approach to treating neurotrophic keratitis (NK) with their gene therapy, KB801. The therapy’s unique mechanism, which utilizes an HSV-1-based vector to deliver nerve growth factor (NGF), presents a potentially less burdensome alternative to the current standard of care, Oxervate, which requires frequent daily applications and has associated side effects.
Moreover, preclinical studies have shown that KB801 achieves superior NGF expression compared to recombinant NGF treatments, and its effects last longer, suggesting that it could offer more efficient healing with less frequent dosing. The ongoing Phase I/II EMERALD-1 trial, which is well-structured with FDA-validated endpoints, could further demonstrate KB801’s efficacy and safety, potentially allowing for rapid clinical advancement. These promising factors contribute to Corwin’s optimistic outlook and Buy rating for Krystal Biotech’s stock.
According to TipRanks, Corwin is a 3-star analyst with an average return of 1.6% and a 41.54% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Crispr Therapeutics AG.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $240.00 price target.